Unlocking the potential of T cell engagers in solid tumors
Cancer Cell · 2026-05 · 44 (5) · 891-895
DOI: 10.1016/j.ccell.2026.03.011 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancer Cell, 2026-05. Verfasst von Emily Wingrove und 3 weiteren Autor:innen. Beteiligte Einrichtung: Amgen Inc., Thousand Oaks, CA, USA. Hauptthemen laut MEDLINE: Neoplasms, T-Lymphocytes, Immunotherapy. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 15 Literaturangaben. Gefördert von: Amgen.
Abstract (Originalsprache)
T cell engagers (TCEs) represent a targeted immunotherapy approach that is reshaping the cancer treatment landscape. While multiple TCEs are approved for the treatment of patients with hematologic malignancies, TCE development in solid tumors continues to face challenges including target heterogeneity within the tumor, an immunosuppressive microenvironment, on-target toxicity in normal tissues, and complex safety profiles. Target selection, creative protein engineering, and thoughtful clinical design are core principles that will guide future strategies for the next generation of TCE therapeutics.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Amgen Inc., Thousand Oaks, CA, USA.
- Amgen Inc., Thousand Oaks, CA, USA. Electronic address: jsoria01@amgen.com.
Förderung
- Amgen
Zitieren
APA
Wingrove, E., Bailis, J. M., Farago, A. F., & Soria, J. C. (2026). Unlocking the potential of T cell engagers in solid tumors. Cancer Cell, 44(5), 891-895. https://doi.org/10.1016/j.ccell.2026.03.011
Vancouver
Wingrove E, Bailis JM, Farago AF, Soria JC. Unlocking the potential of T cell engagers in solid tumors. Cancer Cell. 2026;44(5):891-895. doi:10.1016/j.ccell.2026.03.011
BibTeX
@article{Wingrove2026,
author = {Wingrove, Emily and Bailis, Julie M and Farago, Anna F and Soria, Jean-Charles},
title = {Unlocking the potential of T cell engagers in solid tumors},
journal = {Cancer Cell},
year = {2026},
volume = {44},
number = {5},
pages = {891--895},
doi = {10.1016/j.ccell.2026.03.011}
}
EUVIMED